MMJ国际公司在大麻被重新归类为附表三之后,推进了林业发展局管制的大麻药物,使亨廷顿和MS治疗的临床试验成为可能。 MMJ International advances FDA-regulated cannabis medicine after marijuana’s reclassification to Schedule III, enabling clinical trials for Huntington’s and MS treatments.

在美国将大麻从附表一改为附表三之后,MMJ国际控股公司正在推进由林业发展局管制的大麻药物,使正规制药研究成为可能。 MMJ International Holdings is advancing FDA-regulated cannabis medicine following the U.S. reclassification of marijuana from Schedule I to Schedule III, enabling formal pharmaceutical research. 该公司多年来一直保持 FDA 和 DEA 合规性，拥有两项针对亨廷顿舞蹈症和多发性硬化症的治疗的积极 IND 申请和 FDA 孤儿药称号。 The company, which has maintained FDA and DEA compliance for years, holds two active IND applications and FDA Orphan Drug Designations for treatments targeting Huntington’s disease and multiple sclerosis. MMJ拥有一个经过全球监测方案认证的实验室、精确剂量技术以及独家国际伙伴关系,能够领导美国的临床试验和欧洲商业化,强调科学重于政治趋势。 With a GMP-certified lab, precision dosing technology, and exclusive international partnerships, MMJ is positioned to lead U.S. clinical trials and European commercialization, emphasizing scientific rigor over political trends.